Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes

Effect of Biphasic Insulin Aspart 50 Compared to Biphasic Insulin Aspart 30 Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

This trial is conducted in Asia. The trial aims to investigate if the blood glucose control of biphasic insulin aspart 50 is at least as effective as treatment with biphasic insulin aspart 30 both in combination with metformin.

Inclusion Criteria:

• Type 2 diabetes
• Currently treated with premix human insulin twice daily with or without oral antidiabetic drugs for at least 3 months
• HbA1c (Glycosylated Haemoglobin A1c) between 7.5% - 12.0% (both inclusive)
• FPG (Fasting Plasma Glucose) higher than 7.0 mmol/L
• BMI (Body Mass Index) 23-40 kg/sq.m (both inclusive)

Exclusion Criteria:

• Metformin contraindications according to local practice
• Systemic use of TZDs (thiazolidinediones) for more than 1 month within 6 months prior to this trial